Clinical trial
Sorafenib and Interferon Alfa in Treating Patients With Metastatic or…
NCT00101114 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00101114 |
|---|---|
| Title | Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer |
| Official title | A Phase II Study of the RAF-Kinase Inhibitor BAY 43-9006 (NSC-724772, IND-69,896) in Combination With Interferon-Alpha 2B in Patients With Advanced Renal Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer |
| Intervention type | Biological, Drug, Other |
| Interventions | sorafenib tosylate, recombinant interferon alfa-2b, laboratory biomarker analysis |
| Enrollment | 55 |
| Start date | Sep 1, 2004 |
| Primary completion | May 1, 2006 |
| First posted | Jan 10, 2005 |
| Last update posted | Feb 28, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: